Rosuvastatin can block pro-inflammatory actions of transgenic human C-reactive protein without reducing its circulating levels
Jazyk angličtina Země Anglie, Velká Británie Médium print
Typ dokumentu časopisecké články, práce podpořená grantem
PubMed
24410968
DOI
10.1111/1755-5922.12061
Knihovny.cz E-zdroje
- Klíčová slova
- C-reactive protein, cardiac inflammation, rosuvastatin, spontaneously hypertensive rat, transgenic,
- MeSH
- antiflogistika farmakologie MeSH
- C-reaktivní protein genetika metabolismus MeSH
- fluorbenzeny farmakologie MeSH
- interleukin-6 krev MeSH
- játra účinky léků metabolismus MeSH
- kardiomyocyty účinky léků imunologie metabolismus MeSH
- krysa rodu Rattus MeSH
- lidé MeSH
- mediátory zánětu krev MeSH
- modely nemocí na zvířatech MeSH
- oxidační stres účinky léků MeSH
- potkani inbrední SHR MeSH
- potkani transgenní MeSH
- pyrimidiny farmakologie MeSH
- regulace genové exprese MeSH
- rosuvastatin kalcium MeSH
- sulfonamidy farmakologie MeSH
- TNF-alfa krev MeSH
- zánět krev genetika imunologie prevence a kontrola MeSH
- zvířata MeSH
- Check Tag
- krysa rodu Rattus MeSH
- lidé MeSH
- mužské pohlaví MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Názvy látek
- antiflogistika MeSH
- C-reaktivní protein MeSH
- fluorbenzeny MeSH
- interleukin-6 MeSH
- mediátory zánětu MeSH
- pyrimidiny MeSH
- rosuvastatin kalcium MeSH
- sulfonamidy MeSH
- TNF-alfa MeSH
AIMS: Statins have antiinflammatory effects and are known to decrease risk of cardiovascular events and to reduce serum levels of C-reactive protein (CRP), a widely studied biomarker and potential mediator of inflammation and heart disease. However, it is unclear whether statins can block pro-inflammatory effects of human CRP independent of their ability to reduce serum levels of human CRP. Here, we investigated whether rosuvastatin could block pro-inflammatory effects of human CRP without reducing circulating levels of human CRP. METHODS AND RESULTS: We studied the antiinflammatory effects of rosuvastatin in spontaneously hypertensive rats (SHR) transgenically expressing human CRP (CRP-transgenic SHR) and in nontransgenic SHR lacking human CRP (nontransgenic SHR). The CRP-transgenic SHR is characterized by increased serum levels of human CRP and inflammation. In the CRP-transgenic strain, we found that rosuvastatin treatment decreased circulating levels of inflammatory response markers IL6 and TNFα without decreasing circulating levels of human CRP. In contrast, in the nontransgenic strain lacking human CRP, rosuvastatin treatment had little or no effect on IL6 and TNFα levels. Rosuvastatin also reduced cardiac inflammation and oxidative tissue damage, reduced epididymal fat mass, and improved adipose tissue lipolysis much more in the CRP-transgenic strain than in the nontransgenic strain. CONCLUSION: Rosuvastatin can protect against pro-inflammatory effects of human CRP in a manner that is not dependent on achieving a reduction in circulating levels of human CRP.
Citace poskytuje Crossref.org